Biocon, Mylan win US court ruling that nullifies Sanofi’s patent

US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insulin Glargine product ‘not infringed’ and ‘invalid’ for lack of written description, said Biocon in a press statement. Semglee is co-developed with Mylan in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Q0W0jJ
via IFTTT